Podcast: Building And Scaling Your Workforce: The Importance Of A Flexible Delivery Model In 2024 & Beyond

Creative Science
• Source: Shutterstock

Talent acquisition plays a central role in fostering creativity and innovation within any organization. In today’s highly competitive and fast-moving life sciences sector, it’s more important than ever. Tune into this free podcast to gain valuable insights on maintaining a competitive edge through innovative recruitment and retention strategies.

Listen now, and explore topics including:

  • The importance of organizational culture, flexible working, a diverse leadership and meaningful work when identifying and retaining talent
  • The current skills gaps in the sector
  • Operational challenges facing life sciences looking to scale on a global level, and the critical role of a flexible staffing model
  • Key considerations when scaling your workforce
  • Balancing scientific and technological expertise in recruitment
  • The impact of emerging technologies, such as gene editing, personalized medicines and AI on talent acquisition
  • Reflections on 2023, and tips for revolutionizing the talent ecosystem in 2025

Citeline · Building And Scaling Your Workforce: The Importance Of A Flexible Delivery Model In 2024 & Beyond

Open Media

More from Leadership

Executives On The Move: Fable Therapeutics Gains CMO From AstraZeneca

Recent moves in the industry include changes at the top at 32 Biosciences, plus new CEOs at Idorsia, Courage Therapeutics and Oncolytics Biotech.

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

Ireland’s Got Biopharma Talent To Keep Leading The Pack

 
• By 

The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By 

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Scrip

In partnership with

Podcast: Navigating the Future of Hepatology Clinical Trials

Join Andrew Warmington, Manufacturing Editor at Citeline, in conversation with Tom Hickey, Director of Therapeutic Strategy at Novotech, a global full-service clinical CRO dedicated to accelerating the development of advanced and novel therapeutics.

In partnership with

Podcast Series: Navigating Regulatory Changes & Market Dynamics: CRO Perspectives on the Future of Clinical Trials

Insights from Novotech on Evolving Trends Impacting Global Clinical Development

Sponsored by:

Making medicines more affordable to the NHS

Delve into the challenges facing the NHS, from rising medicine costs to supply shortages, and how generics and branded generics can provide solutions for a more sustainable healthcare system

Sponsored by:

Japan’s Strengths As A Clinical Study Location And Why Selecting The Right Partner Is Crucial

Learn about the critical role the right CRO plays in successfully navigating the significant drug development opportunities in Japan.